Navigation Links
Phase III study finds investigational agent empagliflozin significantly reduced blood glucose in adults with type 2 diabetes and impaired kidney function
Date:6/22/2013

arge cardiovascular outcome trial.

About Diabetes
Approximately 25.8 million Americans2 and an estimated 371 million people worldwide3 have type 1 or type 2 diabetes. T2D is the most common type, accounting for an estimated 90 to 95 percent of all diabetes cases.2 Diabetes is a chronic condition that occurs when the body does not properly produce or use the hormone insulin4. Diabetes was estimated to cost the U.S. $245 billion in direct medical costs and reduced productivity in 2012.5

Boehringer Ingelheim and Eli Lilly and Company
In January 2011, Boehringer Ingelheim and Eli Lilly and Company announced an alliance in the field of diabetes that centers on three compounds representing several of the largest diabetes treatment classes. This alliance leverages the companies' strengths as two of the world's leading pharmaceutical companies, combining Boehringer Ingelheim's solid track record of research-driven innovation and Lilly's innovative research, experience, and pioneering history in diabetes. By joining forces, the companies demonstrate commitment in the care of people with diabetes and stand together to focus on patient needs. Find out more about the alliance at www.boehringer-ingelheim.com or www.lilly.com.

About Boehringer Ingelheim
Boehringer Ingelheim Pharmaceuticals, Inc., based in Ridgefield, CT, is the largest U.S. subsidiary of Boehringer Ingelheim Corporation (Ridgefield, CT) and a member of the Boehringer Ingelheim group of companies.

The Boehringer Ingelheim group is one of the world's 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 140 affiliates and more than 46,000 employees. Since it was founded in 1885, the family-owned co
'/>"/>

SOURCE Eli Lilly and Company; Boehringer Ingelheim Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Phase III studies show linagliptin improved blood glucose control in Asian adults with type 2 diabetes
2. Phase III data show investigational compound empagliflozin significantly reduced blood glucose in adults with type 2 diabetes
3. Follow-up Phase II Data Analysis Adds to Body of Evidence for Investigational Novel Basal Insulin, LY2605541
4. Phase III data show significant reduction in blood glucose with investigational compound empagliflozin added to metformin or metformin plus sulfonylurea in adults with type 2 diabetes
5. Sanofi Announces Positive Phase 3 Data for Once-Daily Lixisenatide for Type 2 Diabetes
6. Ibrutinib Phase 2 Study Results in Patients with Mantle Cell Lymphoma Published in The New England Journal of Medicine
7. Safinamide Phase III Study Results Presented at 2013 MDS Meeting
8. Adamas Pharmaceuticals Presents Positive Phase 2/3 Results For ADS-5102 For The Treatment Of Levodopa-Induced Dyskinesia (LID) In Parkinsons Disease
9. Vanda Presents Data From Phase III Studies that Demonstrate Tasimelteon Restores Daily Cortisol Rhythm In Blind Patients With Non-24-Hour Disorder
10. AbbVie Presents Preliminary Results from Phase I Study of Investigational Oncology Compound ABT-199/GDC-0199 in Patients with High-Risk Chronic Lymphocytic Leukemia (CLL) at European Hematology Association Annual Meeting
11. Updated Results of Two Phase 2 Ibrutinib Studies in Patients with Mantle Cell Lymphoma or Diffuse Large B-cell Lymphoma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/30/2015)... , April 30, 2015 /PRNewswire/ - Pivotal Therapeutics ... company with a focus on Omega-3 therapies for ... operational highlights and financial results for the fiscal ... referenced herein are in Canadian dollars unless otherwise ... been significant, with the right strategic partners and ...
(Date:4/30/2015)... April 30, 2015  Tandem Diabetes Care ® , Inc. ... of the t:slim ® and t:flex™ Insulin Pumps, today ... 2015. In comparing the first quarter of ... grew 53 percent to $12.3 million from $8.1 million ... from 1,723 pumps "Our investment in resources to ...
(Date:4/30/2015)... 30, 2015  Nektar Therapeutics (Nasdaq: NKTR ) ... ended March 31, 2015. Cash and ... $325.8 million as compared to $262.8 million at December ... at March 31, 2015 includes a $100.0 million milestone ... first commercial sale of Movantik™(naloxegol) in the U.S. ...
Breaking Medicine Technology:Pivotal Therapeutics Announces 2014 Financial Results 2Pivotal Therapeutics Announces 2014 Financial Results 3Pivotal Therapeutics Announces 2014 Financial Results 4Pivotal Therapeutics Announces 2014 Financial Results 5Pivotal Therapeutics Announces 2014 Financial Results 6Tandem Diabetes Care Reports First Quarter 2015 Financial Results 2Tandem Diabetes Care Reports First Quarter 2015 Financial Results 3Tandem Diabetes Care Reports First Quarter 2015 Financial Results 4Tandem Diabetes Care Reports First Quarter 2015 Financial Results 5Tandem Diabetes Care Reports First Quarter 2015 Financial Results 6Nektar Therapeutics Reports Financial Results for the First Quarter of 2015 2Nektar Therapeutics Reports Financial Results for the First Quarter of 2015 3Nektar Therapeutics Reports Financial Results for the First Quarter of 2015 4Nektar Therapeutics Reports Financial Results for the First Quarter of 2015 5Nektar Therapeutics Reports Financial Results for the First Quarter of 2015 6Nektar Therapeutics Reports Financial Results for the First Quarter of 2015 7Nektar Therapeutics Reports Financial Results for the First Quarter of 2015 8Nektar Therapeutics Reports Financial Results for the First Quarter of 2015 9Nektar Therapeutics Reports Financial Results for the First Quarter of 2015 10Nektar Therapeutics Reports Financial Results for the First Quarter of 2015 11Nektar Therapeutics Reports Financial Results for the First Quarter of 2015 12
... voluntary recall of ALL lots of its Ketorolac Tromethamine Injection, USP ... NDC# 0517-0601-25 15 mg/mL ... This recall is in addition to the voluntary recall initiated on ... unexpired lots of Ketorolac Tromethamine Injection, USP, 30 mg/mL ...
... a next-generation oncology diagnostics company focused on improving ... closed a $21 million series A financing. ... and included Bessemer Venture Partners, Physic Ventures and ... ) , On-Q-ity is developing diagnostics to determine ...
Cached Medicine Technology:American Regent Expands Voluntary Recall to Include All Lots of Ketorolac Tromethamine Injection, USP 15 mg/mL; 1mL Single Dose Vials 2Cancer Diagnostics Company, On-Q-ity, Raises $21M in Series A Funding for the Development of Technologies to Personalize Cancer Therapy 2
(Date:5/2/2015)... 02, 2015 ZoomCare, the Portland-based innovator ... plans to offer its new healthcare insurance to individuals ... Personal Health Insurance System is the nation’s first health ... human performance. ZOOM+ Personal Health Insurance was ZoomCare’s first ... that are subject to review and regulation by the ...
(Date:5/1/2015)... IDLife LLC, a health and wellness ... the addition of its newest partner and fitness celebrity, ... athlete, growing up in gymnastics and competitive diving, but ... a personal trainer and helping others achieve their fitness ... TV shows highlighting her stunning physique and unique training ...
(Date:5/1/2015)... 01, 2015 Pioneer Millworks, the largest ... latest in their reclaimed wood products at the 27th ... Javits Center in NYC this May. Their newest offerings, ... much anticipated texture and color to North America's platform ... of texture and color in the design world and ...
(Date:5/1/2015)... ME (PRWEB) May 01, 2015 Royal ... in Freeport, Maine, reports on a new study that ... stiffness, joint swelling and improved physical function as well ... with severe osteoarthritis of the knee. , The report ... Natural Insights for Well Being® ,” which Royal River ...
(Date:5/1/2015)... 01, 2015 TROY Healthcare Solutions is ... Regional User Group (RUG) Conference in Atlanta, GA from ... User Group Conference provides a forum for client-to-client presentations, ... all aspects of electronic medical record operations, as well ... applications. , In addition to sponsoring the event, TROY ...
Breaking Medicine News(10 mins):Health News:ZoomCare Applies to be on Oregon Exchange 2Health News:IDLife LLC Announces New Partnership with Fitness Celebrity, Jen Widerstrom 2Health News:Intensely Textured Reclaimed Wood to be Unveiled at ICFF in NYC by Pioneer Millworks 2Health News:Intensely Textured Reclaimed Wood to be Unveiled at ICFF in NYC by Pioneer Millworks 3Health News:New Study Finds Nutrients Ease Arthritis Pain, Retailer Reports 2Health News:TROY Healthcare to Exhibit at the Cerner Southeast Regional User Group Conference 2Health News:TROY Healthcare to Exhibit at the Cerner Southeast Regional User Group Conference 3
... stress may take a toll on your heart, researchers say, ... in long hours at work increase their risk of dying ... In fact, people who work three or more hours of ... heart-related problems such as dying from heart disease, having a ...
... ... manager spends up to 40% of the workweek addressing employee conflict? Conflict ... a new chord by providing a resource for managers to outsource their ... the equivalent of up to two (2) business days a week worth ...
... ... Interpretive Dance Video. , ... Seattle, WA (PRWEB) May 11, 2010 -- Onlineshoes.com is proud to announce the ... featuring an interpretive dance video. , , ,Pronounced “cushy”, Cushe is a new ...
... Melanoma and other ... linked to cancer risk. Practical and clinical information about skin health, melanoma and skin cancer ... , ... With skin cancer on the rise for Americans under 30 and indoor tanning contributing to ...
... ... ... the MTA is keeping some residents in Brooklyn up at night. Meg Richichi has been calling ... attorneys in New York are familiar with the compromise between construction safety and convenience., , ...
... ... Coral Gables (Miami) Florida, Medical Equipment Solutions has been providing services ... Their experts have a passion for helping customers improve their quality ... and oxygen concentrators, the specialists at MES have the experience to ...
Cached Medicine News:Health News:Overtime Boosts Heart Attack Risk 2Health News:Overtime Boosts Heart Attack Risk 3Health News:Conflict Boss Brings Sanity Back to the Workplace and Lets Managers Get Back to Managing 2Health News:Onlineshoes.com and Cushe Team Up to Offer Men and Women Shoes for Casual Living 2Health News:Onlineshoes.com and Cushe Team Up to Offer Men and Women Shoes for Casual Living 3Health News:Skincancer.com Launches With Latest News, Information and Help for Consumers/Patients and Physicians 2Health News:Skincancer.com Launches With Latest News, Information and Help for Consumers/Patients and Physicians 3Health News:New York Construction Accident Attorney, David Perecman, Supports MTA Night Work 2Health News:Miami's Medical Equipment Solutions Now Offers Electric Power Wheelchair 2Health News:Miami's Medical Equipment Solutions Now Offers Electric Power Wheelchair 3Health News:Miami's Medical Equipment Solutions Now Offers Electric Power Wheelchair 4Health News:Miami's Medical Equipment Solutions Now Offers Electric Power Wheelchair 5
Make better prescribing decisions with this drug interaction analyzer containing over 3,000 brand names with generic equivalents....
... Guide for Physicians - ... Integrated Calculators - combines ... and practical drug resource ... dosing calculation tools for ...
AnesthesiaDrugs™ is the handheld version of Sota Omoigui's Anesthesia Drugs Handbook, the best selling clinical guide to essential anesthesia and critical care drug information....
... drug information reference that integrates ... patient care guidelines., The sixth ... 4,700 drugs, including the latest ... indications, dosages, side effects and ...
Medicine Products: